General Information of Drug (ID: DM1FLHH)

Drug Name
Zenocutuzumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM1FLHH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [3]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [4]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [5]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [6]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [7]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [8]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [9]
Tucatinib DMBESUA HER2-positive breast cancer 2C60-2C65 Approved [10]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [11]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [13]
MEHD-7945A DMHOF7T Colorectal cancer 2B91.Z Phase 2 [14]
Seribantumab DMYT470 Colorectal cancer 2B91.Z Phase 2 [15]
CDX-3379 DM5GKYD Squamous cell carcinoma 2B60-2D01 Phase 2 [15]
MM-121 DMDJRU1 Breast cancer 2C60-2C65 Phase 2 [16]
Elisidepsin DMB38KH Psoriasis vulgaris EA90 Phase 2 [17]
Sym013 DMZM6I2 Epithelial ovarian cancer 2B5D Phase 1/2 [18]
Zenocutuzomab DMMQGPE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [19]
LJM716 DMGTB5N Breast cancer 2C60-2C65 Phase 1/2 [20]
AMG888/U3-1287 DMEF4L5 Non-small-cell lung cancer 2C25.Y Phase 1/2 [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [2]
Erbb3 tyrosine kinase receptor (Erbb-3) TTDC8N2 ERBB3_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health.
2 Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12(5):1233-1247.
3 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
5 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
11 Clinical pipeline report, company report or official report of Roche (2009).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
14 Company report (Biooncology)
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Company report (Merrimack)
17 Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Clinical pipeline report, company report or official report of Merus.
20 An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).